Therapy-Induced Senescence Enhances the Efficacy of HER2-Targeted Antibody-Drug Conjugates in Breast Cancer

Antibody-drug conjugates (ADC) are antineoplastic agents recently introduced into the antitumor arsenal. T-DM1, a trastuzumab-based ADC that relies on lysosomal processing to release the payload, is approved for HER2-positive breast cancer. Next-generation ADCs targeting HER2, such as [vic-]trastuzu...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Cancer research (Chicago, Ill.) Ill.), 2022-12, Vol.82 (24), p.4670-4679
Hauptverfasser:	Duro-Sánchez, Santiago, Nadal-Serrano, Mercedes, Lalinde-Gutiérrez, Marta, Arenas, Enrique Javier, Bernadó Morales, Cristina, Morancho, Beatriz, Escorihuela, Marta, Pérez-Ramos, Sandra, Escrivá-de-Romaní, Santiago, Gandullo-Sánchez, Lucía, Pandiella, Atanasio, Esteve-Codina, Anna, Rodilla, Verónica, Dijcks, Fred A, Dokter, Wim H A, Cortés, Javier, Saura, Cristina, Arribas, Joaquín
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Antineoplastic Agents - pharmacology Antineoplastic Agents - therapeutic use Breast Neoplasms - drug therapy Cathepsin B - metabolism Cell Line, Tumor Female Humans Immunoconjugates - pharmacology Immunoconjugates - therapeutic use Receptor, ErbB-2 - metabolism Translational Science Trastuzumab - pharmacology Trastuzumab - therapeutic use Xenograft Model Antitumor Assays
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!